Protease inhibitors, however, require a much higher dose to effectively control HIV-1 infection in macrophages than in CD4+ T-cells, and it is unknown if they achieve the concentrations needed to inhibit macrophage mediated HIV-1 production in compartments such as CNS or testes. The gene discussed is CD4; the disease is HIV-1 infection.